IPSC

Over the past six months, Century Therapeutics' stock (IPSC) has experienced a stock price increase, with the stock increasing by 130.2% between January 1, 2026, and May 8, 2026. In January 2026, the company completed an oversubscribed $135 million private placement. On March 12, 2026, the company reported its full-year 2025 financial results, highlighting a significant increase in collaboration revenue and a narrowed net loss. Analyst ratings and price targets were maintained with bullish and buy ratings in May 2026, and the price target was increased by 22% on April 22, 2026. On April 30, 2026, Century Therapeutics was selected for an oral presentation of CNTY-813 preclinical data. In the past three months, Century Therapeutics insiders sold $45,488.00 in company stock, with no insider buying reported. A new major risk identified in February 2026 was shareholder dilution, with an increase in shares outstanding by 111% in the past year. The Annual General Meeting is scheduled for June 11, 2026.